Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3  weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety

ConclusionAlthough the triweekly six-course regimen of TCbH achieved a high pCR rate, hematological AEs frequently occurred during the latter part of the chemotherapy course. One-third of patients experienced delayed or discontinued chemotherapy.Clinical registration number:http://www.umin.org.auUMIN000013513.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research